{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T20:01:41Z","timestamp":1774728101395,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T00:00:00Z","timestamp":1548201600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12888-018-2001-7","type":"journal-article","created":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T11:06:28Z","timestamp":1548241588000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A case report of the successful administration of clozapine in the face of myocardial infarction, pulmonary embolism and hyperlipidaemia resulting in the termination of long-term seclusion"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5800-0017","authenticated-orcid":false,"given":"Alex","family":"Till","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ed","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,23]]},"reference":[{"key":"2001_CR1","doi-asserted-by":"publisher","first-page":"g1173","DOI":"10.1136\/bmj.g1173","volume":"348","author":"E Kuipers","year":"2014","unstructured":"Kuipers E, Yesufu-Udechuku A, Taylor C, et al. Management of psychosis and schizophrenia in adults: summary of updated NICE guidance. BMJ. 2014;348:g1173.","journal-title":"BMJ"},{"issue":"9","key":"2001_CR2","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","volume":"45","author":"J Kane","year":"1988","unstructured":"Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789\u201396.","journal-title":"Arch Gen Psychiatry"},{"issue":"Suppl","key":"2001_CR3","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1007\/BF00442563","volume":"99","author":"HY Meltzer","year":"1989","unstructured":"Meltzer HY, Bastani B, Kwon KY, et al. A prospective study of clozapine in treatment-resistant schizophrenic patients I preliminary report. Psychopharmacology. 1989;99(Suppl):S68\u201372.","journal-title":"Psychopharmacology"},{"issue":"9","key":"2001_CR4","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1017\/S146114571100201X","volume":"15","author":"C Frogley","year":"2012","unstructured":"Frogley C, Taylor D, Dickens G, et al. A systematic review of the evidence of clozapine's anti-aggressive effects. Int J Neuropsychopharmacol. 2012;15(9):1351\u201371.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"2001_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/00131746-200301000-00003","volume":"9","author":"WA Fisher","year":"2003","unstructured":"Fisher WA. Elements of successful restraint and seclusion reduction programs and their application in a large, urban, state psychiatric hospital. J Psychiatr Pract. 2003;9(1):7\u201315.","journal-title":"J Psychiatr Pract"},{"issue":"1","key":"2001_CR6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3109\/10398560903254193","volume":"18","author":"G Malhi","year":"2010","unstructured":"Malhi G, Adams D, Plain J, et al. Clozapine and cardiometabolic health in chronic schizophrenia: correlations and consequences in a clinical context. Australas Psychiatry. 2010 Feb;18(1):32\u201341.","journal-title":"Australas Psychiatry"},{"issue":"2","key":"2001_CR7","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1093\/schbul\/sbr148","volume":"39","author":"AJ Mitchell","year":"2013","unstructured":"Mitchell AJ, Vancampfort D, Sweers K, et al. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis. Schizophr Bull. 2013 Mar;39(2):306\u201318.","journal-title":"Schizophr Bull"},{"key":"2001_CR8","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S0140-6736(00)02066-3","volume":"355","author":"S H\u00e4gg","year":"2000","unstructured":"H\u00e4gg S, Spigset O, S\u00f6derstr\u00f6m TG. Association of venous thromboembolism and clozapine. Lancet. 2000;355:1155\u20136.","journal-title":"Lancet"},{"issue":"16","key":"2001_CR9","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1093\/eurheartj\/ehu263","volume":"36","author":"R Brauer","year":"2015","unstructured":"Brauer R, Smeeth L, Anaya-Izquierdo K, et al. Antipsychotic drugs and risks of myocardial infarction: a self-controlled case series study. Eur Heart J. 2015;36(16):984\u201392.","journal-title":"Eur Heart J"},{"key":"2001_CR10","first-page":"887","volume":"6","author":"K Lacut","year":"2008","unstructured":"Lacut K. Association between antipsychotic drugs, antidepressant drugs, and venous thromboembolism. Clin Adv Hematol Oncol. 2008;6:887\u201390.","journal-title":"Clin Adv Hematol Oncol"},{"key":"2001_CR11","doi-asserted-by":"publisher","first-page":"c4245","DOI":"10.1136\/bmj.c4245","volume":"341","author":"C Parker","year":"2010","unstructured":"Parker C, Coupland C, Hippisley-cox J. Antipsychotic drugs and risk of venous thromboembolism: nested case-control study. BMJ. 2010;341:c4245.","journal-title":"BMJ"},{"key":"2001_CR12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/pds.2210","volume":"21","author":"B Allenet","year":"2012","unstructured":"Allenet B, Schmidlin S, Genty C, et al. Antipsychotic drugs and risk of pulmonary embolism. Pharmacoepidemiol Drug Saf. 2012;21:42\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9690","key":"2001_CR13","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S0140-6736(09)60742-X","volume":"374","author":"J Tiihonen","year":"2009","unstructured":"Tiihonen J, L\u00f6nnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374(9690):620\u20137.","journal-title":"Lancet"},{"key":"2001_CR14","doi-asserted-by":"publisher","unstructured":"Till A, Selwood J, Silva E. The assertive approach to clozapine: Nasogastric administration. BJPsych Bulletin:1\u20136. \n                    https:\/\/doi.org\/10.1192\/bjb.2018.61\n                    \n                  .","DOI":"10.1192\/bjb.2018.61"},{"key":"2001_CR15","volume-title":"The stationary office","author":"Department of Health","year":"2015","unstructured":"Department of Health. Mental Health Act 1983: Code of Practice. Department of Health. In: The stationary office. London: UK; 2015."},{"key":"2001_CR16","unstructured":"National Institute for Health and Care Excellence (NICE) guideline [CG172]: Myocardial infarction: cardiac rehabilitation and prevention of further MI. NICE 2013, UK."},{"key":"2001_CR17","unstructured":"British National Formulary. Available at: \n                    https:\/\/bnf.nice.org.uk\/drug\/clozapine.html"},{"key":"2001_CR18","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1176\/appi.ajp.2015.15030332","volume":"173:2","author":"TS Stroup","year":"2016","unstructured":"Stroup TS, Gerhard T, Crystal S, et al. Comparative Effectiveness of Clozapine and Standard Antipsychotic Treatment in Adults With Schizophrenia. American Journal of Psychiatry. 2016;173:2:166\u201373.","journal-title":"American Journal of Psychiatry"},{"key":"2001_CR19","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1177\/0269881108100320","volume":"24","author":"J Nielsen","year":"2010","unstructured":"Nielsen J, Dahm M, Lublin H, et al. Psychiatrists\u2019 attitude towards and knowledge of clozapine treatment. Journal of Psychopharmacology. 2010;24:965\u201371.","journal-title":"Journal of Psychopharmacology"},{"issue":"4","key":"2001_CR20","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1192\/apt.bp.116.016147","volume":"23","author":"E Silva","year":"2017","unstructured":"Silva E, Till A, Adshead G. Ethical dilemmas in psychiatry: when teams disagree. BJPsych Advances. 2017;23(4):231\u20139.","journal-title":"BJPsych Advances"},{"issue":"2","key":"2001_CR21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2307\/1914185","volume":"47","author":"D Kahneman","year":"1979","unstructured":"Kahneman D, Tversky A. Prospect theory: an analysis of decision under risk. Econometrica. 1979;47(2):263\u201391.","journal-title":"Econometrica"},{"key":"2001_CR22","first-page":"5","volume":"5","author":"P Foot","year":"1967","unstructured":"Foot P. The problem of abortion and the doctrine of double effect. Oxford Review. 1967;5:5\u201315.","journal-title":"Oxford Review"},{"key":"2001_CR23","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1192\/apt.bp.110.008128","volume":"17","author":"H Mistry","year":"2011","unstructured":"Mistry H, Osborn D. Underuse of clozapine in treatment-resistant schizophrenia. Adv Psychiatr Treat. 2011;17:250\u20135.","journal-title":"Adv Psychiatr Treat"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-018-2001-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12888-018-2001-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-018-2001-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T19:09:57Z","timestamp":1579720197000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-018-2001-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,23]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2001"],"URL":"https:\/\/doi.org\/10.1186\/s12888-018-2001-7","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,23]]},"assertion":[{"value":"13 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the editor of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ES has received speaker fees from Jansen Pharmaceuticals and Novartis (none since 2009).AT has no competing interests to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"37"}}